IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo vs sunitinib.

A trend towards improvement in overall survival (OS) was observed in patients treated with Cylembio plus pembrolizumab (OS not yet mature), HR=0.79 (CI 0.57-1.10) Cylembio plus pembrolizumab was well ...

IO Biotech (NASDAQ:IOBT) stock gained 6.1% after revealing topline data from its pivotal Phase 3 trial evaluating Cylembio, ...

IO Biotech reported its phase 3 trial readout on melanoma immunotherapy. Check out my updated investment thesis on IOBT stock ...

Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for ...

The Copenhagen-based company on Monday said top-line results from the phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio, demonstrated clinical ...

An expert discusses how community-based gene therapy administration has broadened treatment options for patients with ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025 ...

A new treatment for advanced endometrial cancer has been approved for use on the NHS, after women with the disease were found ...

Background: Patients with advanced melanoma who progress on PD-1 and CTLA-4 inhibitors (IO-R/R) have poor prognosis. Gotistobart is a pH-sensitive anti-CTLA-4 mAb and we hypothesized that gotistobart ...

Treatment with pembrolizumab plus enfortumab vedotin reduced the risk of disease progression or death by 55% compared with chemotherapy. The Food and Drug Administration (FDA) has accepted for ...